Berberine for antipsychotic-induced metabolic syndrome in patients with schizophrenia spectrum disorders: abridged secondary publication

Hong Kong Med J. 2023 Jun;29 Suppl 3(3):4-7.

Authors

M Y Chan¹, S C Man¹, M Lam², W H Lai², Z S Qin¹, M K R Ng³, C K Lee³, Y H E Chen⁴, H M E Lee⁴, L Y Liu⁵, H K Wong¹, Z J Zhang¹

Affiliations

¹ School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
² Department of Adult Psychiatry, Castle Peak Hospital, Hong Kong SAR, China.
³ Department of Psychiatry, Kowloon Hospital, Hong Kong SAR, China.
⁴ Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
⁵ Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.

PMID: 37357582

No abstract available

MeSH terms

Antipsychotic Agents* / adverse effects
Berberine* / adverse effects
Humans
Metabolic Syndrome* / chemically induced
Metabolic Syndrome* / complications
Schizophrenia* / drug therapy

Substances

Antipsychotic Agents
Berberine